Shopping Cart
- Remove All
Your shopping cart is currently empty
Dehydrocavidine
😃Good
Catalog No. TN1139Cas No. 83218-34-2
Alias Dehydrocorydaline
Dehydrocavidine (Dehydrocorydaline) has antitumor activity, it inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP.
Dehydrocavidine
😃Good
Catalog No. TN1139Alias DehydrocorydalineCas No. 83218-34-2
Dehydrocavidine (Dehydrocorydaline) has antitumor activity, it inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $207 | 7-10 days | |
| 5 mg | $465 | 7-10 days | |
| 10 mg | $698 | 7-10 days | |
| 25 mg | $1,255 | 7-10 days | |
| 50 mg | $1,890 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Dehydrocavidine"
Olaparib
Cited
KU0059436, AZD2281
T3015763113-22-0
Olaparib (KU0059436) is a small molecule inhibitor of PARP1/PARP2 (IC50=5/1 nM), with weak inhibitory activity against PARP tankyrase-1 (IC50=1.5 μM), and is selective and orally active. Olaparib exhibits autophagy and mitochondrial autophagy activation activity.
- $31
Size
QTY
CitedOUL35
NSC39047
T90246336-34-1
OUL35 (NSC-39047) is a selective PARP-10 inhibitor, and small-molecule ARTD10 inhibitor. OUL35 has been shown to rescue cells from ARTD10-induced cell death.
- $31
Size
QTY
Talazoparib Cited
LT-673, BMN-673
T62531207456-01-6
Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).
- $35
Size
QTY
CitedVenetoclax Cited
GDC-0199, ABT-199, ABT199, ABT 199
T21191257044-40-8
Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
- $48
Size
QTY
CitedLisaftoclax
Bcl-2/Bcl-xl inhibitor 1, APG-2575
T104832180923-05-9
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
- $187
Size
QTY
XAV-939 Cited
XAV939, NVP-XAV939
T1878284028-89-3
XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
- $48
Size
QTY
CitedThymoquinone
Thymoquinon, NSC 2228
T4088490-91-5
Thymoquinone (NSC 2228) is a compound be found in herbs and spices with anti-inflammatory and anti-oxidant effects.
- $29
Size
QTY
Niraparib Cited
MK-4827
T32311038915-60-4
Niraparib (MK-4827) is a PARP inhibitor that selectively targets PARP1 and PARP2 (IC50=3.8/2.1 nM), exhibiting antitumor activity, inhibiting DNA damage repair, and inducing apoptosis.
- $55
Size
QTY
CitedNavitoclax Cited
ABT-263
T2101923564-51-6
Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.
- $41
Size
QTY
Cited3-Aminobenzamide
PARP-IN-1, INO-1001, INO1001, INO 1001, 3-ABA, 3-AB
T63293544-24-9
3-Aminobenzamide (PARP-IN-1) is a potent PARP inhibitor (IC50 < 50 nM in CHO cells) and mediates oxidant-induced myocyte dysfunction during reperfusion.
- $37
Size
QTY
Benzamide
Phenylcarboxyamide, Benzoylamide, Amid kyseliny benzoove
T678055-21-0
Benzamide (Amid kyseliny benzoove), an inhibitor of poly(ADP-ribose) polymerase, is a derivative of benzoic acid.
- $30
Size
QTY
(S)-(+)-Ibuprofen
Dexibuprofen, (S)-Ibuprofen
T044851146-56-6
(S)-(+)-Ibuprofen (Dexibuprofen) , is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
- $35
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Dehydrocavidine (Dehydrocorydaline) has antitumor activity, it inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. |
| In vitro | The complexation behavior of palmatine (P) and Dehydrocorydaline (DHC) alkaloid guest molecules by cucurbit[7]uril (CB7) host have been investigated by means of fluorescence spectra in aqueous phosphate buffer solution (pH 7.2). It is found that each alkaloid exhibits dramatic fluorescence enhancement upon complexation with CB7, and the intensity of the emittance is strong enough to be readily distinguished by the naked eye. Although the two guests possess similar structure, the complex stability constant of P with CB7 is 5.4 times larger than that of DHC. |
| Alias | Dehydrocorydaline |
| Molecular Weight | 348.37 |
| Formula | C21H18NO4 |
| Cas No. | 83218-34-2 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Dehydrocavidine | purchase Dehydrocavidine | Dehydrocavidine cost | order Dehydrocavidine | Dehydrocavidine chemical structure | Dehydrocavidine in vitro | Dehydrocavidine formula | Dehydrocavidine molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.